Research on Effect and Mechanism of Xuefu Zhuyu Decoction on CHD Based on Meta-Analysis and Network Pharmacology

Abstract

Xuefu Zhuyu Decoction (XFZY) is an ancient compound widely used in the treatment of coronary heart disease. However, its efficacy evaluation is not complete and its mechanism of action is not clear enough. In an attempt to address these problems, the efficacy was evaluated by meta-analysis and the mechanism was elucidated by the network pharmacology method. We systematically searched relevant studies in PubMed, Chinese National Knowledge Infrastructure Database (CNKI), Cochrane Library, Wanfang Data, and other databases from 2007 to 2019. The association between XFZY treatment and CHD was estimated by risk ratio (RR) and corresponding 95% confidence intervals (95% CIs). The compounds and the potential protein targets of XFZY were obtained from TCMSP, and active compounds were selected according to their oral bioavailability and drug similarity. The potential genes of coronary heart disease were obtained from TTD, OMIM, and GeneCards. The potential pathways related to genes were determined by GO and KEGG pathway enrichment analyses. The compound-target and compound-target-pathway networks were constructed. Molecular docking validates the component and the target. A total of 21 studies including 1844 patients were enrolled in the present meta-analysis, indicating that XFZY has a greater beneficial on total effect (fixed effect RR = 1.30; 95% Cl: 1.24–1.36; P = 0.82 ; I2 = 0.0%) and electrocardiogram efficacy (fixed effect RR = 1.40; 95% Cl: 1.26–1.56; P = 0.96 ; I2 = 0.0%) compared with the control group. A total of 1342 components in XFZY were obtained, among which, 241 were chosen as bioactive components. GO and KEGG analyses got top 10 significantly enriched terms and 10 enriched pathways. The C-T network included 192 compounds and 3085 targets, whereas the C-T-P network included 10 compounds, 109 targets, and 5 pathways. There was a good binding activity between the components and the targets. XFZY has the curative effect on coronary heart disease, and its mechanism is related to 10 compounds, 10 core targets, and 5 pathways.

The Mechanism Action of German Chamomile (Matricaria recutita L.) in the Treatment of Eczema: Based on Dose–Effect Weight Coefficient Network Pharmacology

“…Taking “eczema” as the keyword and setting the species as humans, we searched the GeneCards database ( Liu et al, 2020 ), DisGeNET database ( Wu et al, 2020 ), OMIM database ( Kui et al, 2021 ), and Comparative Toxicogenomics Database (CTD) ( Tianmu et al, 2021 ) to identify the qualified information of genes and target proteins related to eczema.…”

“…Based on the GEO database GSE57225 chip detection data ( Liang et al, 2021 ), the data set included 23 patients and 17 normal control samples. The differential gene expression was analyzed using Limma software package 15 of R. The screening criteria were | logFC | > 1.2 and p < 0.05.…”

The Effect and Safety of Xuefu Zhuoyue Prescription for Coronary Heart Disease: An Overview of Systematic Reviews and Meta-Analyses

“…A total of 78 publications were obtained from seven electronic databases after the search; among those, 45 were excluded after duplicates removal, 17 were excluded by screening the titles and abstracts, and 7 [22][23][24][25][26][27][28] were further excluded after the full text was read due to their failure to meet the intervention criteria. Finally, 11 publications [29][30][31][32][33][34][35][36][37][38][39] were included for the study.…”

Potential active compounds and molecular mechanism of Xuefu Zhuyu decoction for atherosclerosis, based on network pharmacology and molecular docking

“…[ 5 – 7 ] Many diseases, including myocardial fibrosis, AS, hypertension, unstable angina pectoris, and myocardial ischemia-reperfusion injury, have been treated using XFZYD. [ 8 , 9 ] However, more research is needed into the material basis and molecular targets of multicomponent, multichannel, and multitarget XFZYD in the prevention and treatment of as to give an evidence-based foundation for clinical wide application and new drug development.…”